BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30262518)

  • 1.
    Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
    J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Van Weehaeghe D; Koole M; Schmidt ME; Deman S; Jacobs AH; Souche E; Serdons K; Sunaert S; Bormans G; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2051-2064. PubMed ID: 31243495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
    Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M
    J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
    Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
    J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [
    Mertens N; Schmidt ME; Hijzen A; Van Weehaeghe D; Ravenstijn P; Depre M; de Hoon J; Van Laere K; Koole M
    Sci Rep; 2021 Aug; 11(1):16172. PubMed ID: 34373571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of
    Bullich S; Barret O; Constantinescu C; Sandiego C; Mueller A; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Madonia J; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
    J Nucl Med; 2020 Jun; 61(6):920-927. PubMed ID: 31712324
    [No Abstract]   [Full Text] [Related]  

  • 7. PET Imaging of the P2X7 Ion Channel with a Novel Tracer [
    Berdyyeva T; Xia C; Taylor N; He Y; Chen G; Huang C; Zhang W; Kolb H; Letavic M; Bhattacharya A; Szardenings AK
    Mol Imaging Biol; 2019 Oct; 21(5):871-878. PubMed ID: 30632003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characterization of [
    Constantinescu CC; Brown T; Wang S; Yin W; Barret O; Jennings D; Tauscher J
    J Nucl Med; 2023 Dec; 64(12):1972-1979. PubMed ID: 37770111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
    Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
    Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [
    Arakawa R; Takano A; Stenkrona P; Stepanov V; Nag S; Jahan M; Grybäck P; Bolin M; Chen L; Zhang L; He P; Villalobos A; McCarthy TJ; Halldin C; Varrone A
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2429-2439. PubMed ID: 32140803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
    Recourt K; van der Aart J; Jacobs G; de Kam M; Drevets W; van Nueten L; Kanhai K; Siebenga P; Zuiker R; Ravenstijn P; Timmers M; van Gerven J; de Boer P
    J Psychopharmacol; 2020 Sep; 34(9):1030-1042. PubMed ID: 32248747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validation of the novel HDAC6 radiotracer [
    Koole M; Van Weehaeghe D; Serdons K; Herbots M; Cawthorne C; Celen S; Schroeder FA; Hooker JM; Bormans G; de Hoon J; Kranz JE; Van Laere K; Gilbert TM
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):596-611. PubMed ID: 32638097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial Evaluation of an Adenosine A
    Sakata M; Ishibashi K; Imai M; Wagatsuma K; Ishii K; Zhou X; de Vries EFJ; Elsinga PH; Ishiwata K; Toyohara J
    J Nucl Med; 2017 Sep; 58(9):1464-1470. PubMed ID: 28280214
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334.
    Lord B; Ameriks MK; Wang Q; Fourgeaud L; Vliegen M; Verluyten W; Haspeslagh P; Carruthers NI; Lovenberg TW; Bonaventure P; Letavic MA; Bhattacharya A
    Eur J Pharmacol; 2015 Oct; 765():551-9. PubMed ID: 26386289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates.
    Ory D; Celen S; Gijsbers R; Van Den Haute C; Postnov A; Koole M; Vandeputte C; Andrés JI; Alcazar J; De Angelis M; Langlois X; Bhattacharya A; Schmidt M; Letavic MA; Vanduffel W; Van Laere K; Verbruggen A; Debyser Z; Bormans G
    J Nucl Med; 2016 Sep; 57(9):1436-41. PubMed ID: 27199364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
    Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.
    Naganawa M; Jacobsen LK; Zheng MQ; Lin SF; Banerjee A; Byon W; Weinzimmer D; Tomasi G; Nabulsi N; Grimwood S; Badura LL; Carson RE; McCarthy TJ; Huang Y
    Neuroimage; 2014 Oct; 99():69-79. PubMed ID: 24844744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
    Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
    J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation and Quantification of
    Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
    J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
    Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
    Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.